紫草素对乙酰胆碱-氯化钙混合液诱导的房颤大鼠的保护作用研究

王钥; 陈斌; 卢悟广; 蔡蕊; 徐留刚; 黄丹; 曹鹏; 沈建平; 周谦

紫草素对乙酰胆碱-氯化钙混合液诱导的房颤大鼠的保护作用研究

王钥¹,
陈斌²,
卢悟广¹,
蔡蕊¹,
徐留刚¹,
黄丹¹,
曹鹏^1,3,
沈建平¹,
周谦¹

1.
南京中医药大学附属中西医结合医院，江苏南京 210028
2.
南京野生植物综合利用研究院，江苏南京 210042
3.
南京中医药大学药学院，江苏南京 210023

计量
- 文章访问数: 728
- HTML全文浏览量: 12
- PDF下载量: 447
- 被引次数: 0
出版历程
- 刊出日期: 2020-01-10

Protective Effect of Shikonin on Ach-CaCl₂-Induced Atrial Fibrillation in Rats

1.
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, China
2.
Nanjing Research Institute for Comprehensive Utilization of Wild Plants, Nanjing, 210042, China
3.
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China

摘要

摘要: 目的探索紫草素对乙酰胆碱-氯化钙(Ach-CaCl₂）诱导的房颤大鼠的保护作用及可能机制。方法采用雄性SD大鼠尾静脉注射Ach-CaCl₂混合液建立大鼠房颤模型，分为正常对照组、模型组与紫草素组。其中，紫草素组预先1周灌胃给予紫草素4 mg/（kg·d），再与模型组同时给予Ach-CaCl₂混合液造模，采用心电图检测、心脏彩超观察、Masson染色、ELISA法、Western blot等方法评价紫草素对房颤大鼠的保护作用。结果心电图结果显示紫草素延长了大鼠房颤诱发时间，彩超结果显示紫草素改善房颤大鼠心脏扩大情况，ELISA结果显示紫草素降低了房颤大鼠血清炎症因子IL-6和TNF-α水平，Western blot法同样表明紫草素抑制了房颤大鼠心房组织的IL-6和TNF-α的蛋白表达。结论紫草素对房颤大鼠具有保护作用。
- 紫草素 /
- 房颤 /
- 炎症 /
- IL-6 /
- TNF-α
Abstract: OBJECTIVE To evaluate the potential therapeutic effects and mechanism of shikonin on atrial fibrillation in vivo. METHODS Male Sprague-Dawley rats were injected with Ach-CaCl₂ mixture to make atrial fibrillation model. They were divided into blank group， model group and shikonin group. 4 mg/(kg·d) Shikonin was given to the shikonin group by one-week gavage in advance， Then given Ach-CaCl₂mixture at the same time. The effects of shikonin on atrial fibrillation in rats were evaluated by electrocardiogram， color Doppler ultrasound， Masson staining， ELISA and Western blot. RESULTS Electrocardiogram showed that shikonin prolonged the induction time of atrial fibrillation; color ultrasonographic results showed that shikonin improved heart enlargement in rats with atrial fibrillation; shikonin inhibited serum inflammatory factors IL-6 and TNF-α in rats with atrial fibrillation; Western blot also showed that shikonin inhibited the expression of IL-6 and TNF-α in atrial tissue of atrial fibrillation rats. CONCLUSION Shikonin shows a protective effect on a rat model of atrial fibrillation.
- Shikonin /
- atrial fibrillation /
- inflammation /
- IL-6 /
- TNF-α

HTML全文

参考文献(19)

[1]	BORIANI G， DIEMBERGER I， MARTIGNANI C， et al. The epidemiological burden of atrial fibrillation: A challenge for clinicians and health care systems[J]. Eur Heart J， 2006， 27: 893-894.
[2]	BALL J， CARRINGTON MJ， MCMURRAY JJV， et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century[J]. Int J Cardiol， 2013， 167: 1807-1824.
[3]	徐永玄，杨萍，郭涛.房颤发生机制及治疗新进展[J]. 昆明医科大学学报，2019，40（5）：135-138.
[4]	DA SILVA. Influence of inflammation and atherosclerosis in atrial fibrillation[J]. Curr Atherosclerosis Rep， 2017， 19(1): 2.
[5]	PAMUKCU B， LIP GYH. Dronedarone as a new treatment option for atrial fibrillation patients: Pharmacokinetics， pharmacodynamics and clinical practice[J]. Exp Opin Pharm， 2011， 12: 131-140.
[6]	GUO X， CHEN W， SUN H， et al. Kv1. 5 Inhibitors for treatment of atrial fibrillation: A tradeoff between selectivity and non-selectivity[J]. Curr Topics Med Chem， 2016， 16: 1843-1854.
[7]	ANDUJAR I， RIOS JL， GINER RM， et al. Pharmacological properties of shikonin-a review of literature since 2002[J]. Planta Med， 2013， 79: 1685-1697.
[8]	WANG S， ZHU Y， QIU R. Shikonin protects H9C2 cardiomyocytes against hypoxia/reoxygenation injury through activation of PI3K/Akt signaling pathway[J]. Biomed Pharm， 2018， 104: 712-717.
[9]	YANG J， WANG Z， CHEN DL. Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis， inflammation， apoptosis and ER stress[J]. Biomed Pharm， 2017， 93: 1343-1357.
[10]	WANG XH， ZHANG JH， HU YN， et al. Effects of shikonin on apoptosis and oxidative stress of vascular endothelial cells induced by high glucose[J].Chin J Pathophysiol， 2018， 34: 1222-1227.
[11]	WOZAKOWSKA-KAPON B. Changes in left atrial size in patients with persistent atrial fibrillation: A prospective echocardiographic study with a 5-year follow-up period[J]. Int J Cardiol， 2005， 101: 47-52.
[12]	ZHANG YJ， MA N， SU F， et al. Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis[J]. Exp Mol Pathol， 2015， 98: 486-490.
[13]	MAENG YS， LEE GH， CHOI SI， et al. Histone methylation levels correlate with TGFBIp and extracellular matrix gene expression in normal and granular corneal dystrophy type 2 corneal fibroblasts[J]. BMC Med Genom， 2015， 8: 74.
[14]	HARADA M， VAN WAGONER DR， NATTEL S. Role of inflammation in atrial fibrillation pathophysiology and management[J]. Circul J， 2015，79(3):495-502.
[15]	WU N， XU B， XIANG Y， et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis[J]. Int J Cardiol， 2013， 169: 62-72.
[16]	CONWAY DSG， BUGGINS P， HUGHES E， et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation[J]. Am Heart J， 2004， 148: 462-466.
[17]	LI J， SOLUS J， CHEN Q， et al. Role of inflammation and oxidative stress in atrial fibrillation[J]. Heart Rhythm， 2010， 7: 438-444.
[18]	YANG Y， WANG J， YANG Q， et al. Shikonin inhibits the lipopolysaccharide-induced release of HMGB1 in RAW264.7 cells via IFN and NF-κB signaling pathways[J]. Int Immunopharmacol， 2014， 19: 81-87.
[19]	LU L， QIN A， HUANG H， et al. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition[J]. Eur J Pharmacol， 2011， 658: 242-247.